A pair of Lyell founders look to shift the cell therapy paradigm — and they've got $30M to get their plan off the ground
Rick Klausner’s Lyell has taken the cell therapy field by storm, recruiting an All-Star team with the goal of creating the first CAR-Ts for solid tumors. But the company may have been too productive — too good at its job — theorizing more potential therapies than it could handle alone.
As a result, some of that research has been spun out into a new biotech called Outpace Bio, with Lyell founders and former co-directors of cell and protein engineering Marc Lajoie and Scott Boyken, getting things started with a $30 million Series A on Wednesday. Lyell itself is one of the lead investors in the round and is also teaming up with Outpace in a collaboration for T cell therapies against solid tumors.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters